

How Common are Rare Diseases?

Social Survey Research Information

| Estimated Rare Disease Population in Japan | Introduction | Methodology | Results and Discussions | Conclusions We estimated the number of patients suffering from rare dise |
|--|---|---|---|---|
| | pharmaceutical companies as the next frontier in pharmaceutical research and development. However, due to its very nature of being rare. | government as rare and intractable diseases, research and development for which are encouraged and subsidised. | diseases based on Patients Map. The estimated numbers of patients ranged from over 90,000 to under one hundred. 90% of the diseases have more than 1,000 patients and 43% have more than 10.000. | Japan by using the results of a large-scale web surver compared it against the existing figure on patient population. |
| (# of pts) | these diseases have been difficult to understand. In our poster presentation, we will look at the | For the purposes of this poster presentation, we estimated the population suffering from these diseases in the following manner: 1. The prevalence of physicians seeing these rare diseases and the average number of patients managed by those physicians | The row below that with green square shows whether there are any existing publications or estimate for the relevant disease. If the estimate based on Patients Map is within the range of 50% to 200% of a pre- | In some areas our new estimates corroborated the understanding of the patient population. In other are estimates provided a view different from our understanding, or a new reference point where no p |
| 90,000 | estimated patient population of some of the rare diseases, drawing from both primary and secondary information | were obtained from the Patients Map database*. | existing data, a star * * is given in the row below green squares. 23 out of 83 diseases got the stars as a result. | information existed. |
| 90,000 | (This presentation examines rare disease population in Japan only) | different specialities and type of institutions, the nationwide figure of rare disease patient populations were estimated. | Among the diseases with a star, the existing patient population estimate and that based on Patients Map showed close agreement such as below: | basic research. We hope this paper has been of help to s light on this little understood class of diseases. |
| 70,000 | | This estimate was then compared against the information provided by the Japan Intractable Diseases Information Center run by Ministry of Health, Labour and Welfare (if the data exists). | Existing Patients Map Subacute myelo-optico- 2,176 2,103 | Contact |
| 60,000 | | * Patients Map is a database developed by SSRI and m3 on | Acromegaly 10,000 9,226 | Hitoshi Dennoh, Ryusuke Shinozaki Social Survey Research Information |
| 50,000 | | patient number and other aspects based on web-survey with more than 20,000 physicians in Japan, covering 300+ diseases. | The existing figure for subacute myelo-optico-neuropathy is based on the number of patients suffering from this disease receiving healthcare subsidy, and that for acromegaly is based on an epidemiological study | For more details, please come to our booth (No.7) at Age |
| 40,000 | | | conducted in one of prefectures in Japan, extrapolated into a nationwide figure. | 2,500 |
| | | | On the other hand, other discourse produced quite different figures. One | 2 000 |
| 30,000 | | | of the reasons is that existing data are not necessarily a nationwide | 1,500 |
| 30,000 · 20,000 · | | | of the reasons is that existing data are not recessarily a nationwide estimate of patients but rather "identified" patients. In some cases the data were not updated for years. In fact none of the estimates older than 10 years came close to the figure estimated from Patients Map. | |
| 30,000 - 20,000 - 10,000 - | | | of the reasons is that existing data are not necessarily a nationwide estimate of patients but rather "identified" patients. In some cases the data were not updated for years. In fact none of the estimates older than 10 years came close to the figure estimated from Patients Map. | |
| 30,000 20,00000 20,000 20,000 20,000 20,000 20,000 20,000 20,000 20,000 20,0000 | | | of the reasons is that existing data are not necessarily a nationwide estimate of patients but rather "identified" patients. In some cases the data were not updated for years. In fact none of the estimates older than 10 years came close to the figure estimated from Patients Map. | |
| 30,000 c 20,000 c 10,000 c 10,000 c 10,000 c 10 c | | | of the reasons is that existing data are not excessingly a nationwide estimate of patients but rather "identified" patients. In some cases the data were not updated for years. In fact none of the estimates older than 10 years came close to the figure estimated from Patients Map. | |
| 30,000 20,000 10,000 0 mg data on number of pts satients Map estimate within 50-200% of existing data (Chronic protections) Support Light of the satisfies of the satisf | Aertik syndrome Rady progressive gi- Rady progressive gi- Rady progressive syndrome Faher's syndrome Polymrate nodosa Morymray at loase Morymra | Intrivi-associated my Intrivi-associated my Introduction Interview Interview | of the reasons is that existing data are not necessarily a nationwide estimate of patients but rather "identified" patients. In some cases the data were not updated for years. In fact one of the estimates older than 10 years came close to the figure estimated from Patients Map. Cyclic full and the stimates older than 10 years came close to the figure estimated from Patients Map. Cyclic full and the stimates older than 10 years came close to the figure estimated from Patients Map. Cyclic full and the stimates older than 10 years came close to the figure estimated from Patients Map. Cyclic full and the stimates older than 10 years came close to the figure estimated from Patients were stimated Cyclic full and the stimates of the stima | 1,500 1,500 1,500 500 |